271
Views
11
CrossRef citations to date
0
Altmetric
Uveitis

Novel Dexamethasone Sodium Phosphate Treatment (DSP-Visulex) for Noninfectious Anterior Uveitis: A Randomized Phase I/II Clinical Trial

, , , , , , , , & show all
Pages 185-193 | Received 23 May 2018, Accepted 21 Oct 2018, Published online: 15 Nov 2018

References

  • Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5–6):303–08. doi:10.1007/BF00163549.
  • Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SRJ, Joshi L, Lightman S. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(12):2387–92. doi:10.1016/j.ophtha.2014.07.007.
  • Gritz DC, Schwaber EJ, Wong IG. Complications of Uveitis: the Northern California epidemiology of Uveitis Study. Ocul Immunol Inflamm. 2017 Jan;23:1–11. doi:10.1080/09273948.2016.1247174.
  • Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of Uveitis Study. Ophthalmology. 2004;111:491–500. doi:10.1016/j.ophtha.2003.06.014.
  • Acharya NR, Tham VM, Esterberg E, Borkar DS, Parker JV, Vinoya AC, Uchida A. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol. 2013;131(11):1405–12. doi:10.1001/jamaophthalmol.2013.4237.
  • Suhler EB, Lloyd MJ, Choi D, Rosenbaum JT, Austin DF. Incidence and prevalence of Uveitis in veterans affairs medical centers of the Pacific Northwest. Am J Ophthalmol. 2008;146(6):890. doi:10.1016/j.ajo.2008.09.014.
  • Agrawal RV, Murthy S, Sangwan V, Biswas J. Current approach in diagnosis and management of anterior uveitis. Indian J Ophthalmol. 2010;58(1):11–19. doi:10.4103/0301-4738.58468.
  • Foster CS, Kothari S, Anesi SD, Vitale AT, Chu D, Metzinger JL, Cerón O. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Surv Ophthalmol. 2016;61:1–17. doi:10.1016/j.survophthal.2015.07.001.
  • Gutteridge IF, Hall AJ. Acute anterior uveitis in primary care. Clin Exp Optom. 2007;90(2):70–82. doi:10.1111/j.1444-0938.2006.00128.x.
  • Cunningham ET, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol/J Can d’Ophtalmologie. 2010;45(4):352–58. doi:10.3129/i10-081.
  • Airody A, Heath G, Lightman S, Gale R. Non-infectious Uveitis: optimising the therapeutic response. Drugs. 2016;76(1):27–39. doi:10.1007/s40265-015-0502-y.
  • Rodriguez Villanueva J, Rodriguez Villanueva L, Guzman Navarro M. Pharmaceutical technology can turn a traditional drug, dexamethasone into a first-line ocular medicine. A global perspective and future trends. Int J Pharm. 2017;516(1–2):342–51. doi:10.1016/j.ijpharm.2016.11.053.
  • Jager RD, Aiello LP, Patel SC, Cunningham ET. Risks of intravitreous injection: a comprehensive review. Retina. 2004;24(5):676–98. doi:10.1097/00006982-200410000-00002.
  • Sen HN, Vitale S, Gangaputra SS, Nussenblatt RB, Liesegang TL, Levy-Clarke GA, Rosenbaum JT, Suhler EB, Thorne JE, Foster CS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–86. doi:10.1016/j.ophtha.2014.05.021.
  • Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H. Posterior vitreous detachment following intravitreal drug injection. Graefe’s Arch Clin Exp Ophthalmol. 2013;251(7):1691–95. doi:10.1007/s00417-013-2266-y.
  • Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li X-Y, Cui H, Whitcup SM. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–53. doi:10.1001/archophthalmol.2010.339.
  • Winfield AJ, Jessiman D, Williams A, Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br J Ophthalmol. 1990;74( March):477–80. doi:10.1136/bjo.74.8.477.
  • An JA, Kasner O, Samek DA, Lévesque V. Evaluation of eyedrop administration by inexperienced patients after cataract surgery. J Cataract Refract Surg. 2014;40(11):1857–61. doi:10.1016/j.jcrs.2014.02.037.
  • Razeghinejad MR, Katz LJ. Steroid-induced iatrogenic glaucoma. Ophthalmic Res. 2012;47:66–80. doi:10.1159/000328630.
  • Papangkorn K, Prendergast E, Higuchi JW, Brar B, Higuchi WI. Noninvasive ocular drug delivery system of dexamethasone sodium phosphate in the treatment of experimental uveitis rabbit. J Ocul Pharmacol Ther. 2017 Dec;33(10):753–62. doi:10.1089/jop.2017.0053.
  • Papangkorn K, Higuchi JW, Brar B, Higuchi WI. Ocular drug distribution and safety of a noninvasive ocular drug delivery system of dexamethasone sodium phosphate in rabbit. J Ocul Pharmacol Ther. 2018 Feb 12;34(4):325–34. doi:10.1089/jop.2017.0093.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16. doi:10.1016/j.ajo.2005.03.057.
  • Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003;22(7):640–50. doi:10.1097/00003226-200310000-00008.
  • Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26(5):475–83. doi:10.1089/jop.2010.0059.
  • Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: A phase III, multicenter, randomized study. Investig Ophthalmol Vis Sci. 2014;55(5):2993–3002. doi:10.1167/iovs.13-12660.
  • Nichols KK, Mitchell GL, Simon KM, Chivers DA, Edrington TB. Corneal staining in hydrogel lens wearers. Optom Vis Sci. 2002;79(1):20–30. doi:10.1097/00006324-200201000-00009.
  • Fonn D, Peterson RC, Woods CA. Corneal staining as a response to contact lens wear. Eye Contact Lens. 2010;36(5):318–21. doi:10.1097/ICL.0b013e3181f35d54.
  • Schein OD. Adverse reactions associated with contact lens use. In: Flattau PE, editor. Considerations in contact lens use under adverse conditions: proceedings of a symposium. Washington (D.C.): National Academies Press; 1991. p. 58–67.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.